Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Datamonitor Reports | Pipeline Insight: Benign Prostatic Hyperplasia - Novel therapeutics and reformulations will drive market growth

Pipeline Insight: Benign Prostatic Hyperplasia - Novel therapeutics and reformulations will drive market growth

BPH is a chronic urological condition involving the non-cancerous enlargement of the prostate affecting over 15 million men across the seven major markets. The market for BPH drugs that aim to alleviate the symptoms and reduce prostate size was worth $3.7bn in 2008. The BPH market is expected to continue growing over the next 10 years driven by the launch of new improved treatments.

Analysis of BPH etiology, symptomology, diagnosis, treatment, current and future prevalence, and the key unmet market needs.

Review of the complete pre-clinical and clinical pipeline for new BPH therapies, including analysis of key R&D company strategies.

In depth analysis of historic (200408) and future (20092018) market dynamics, including profiles of Flomax and Avodart (dutasteride).

Commercial and clinical assessment of key late-stage pipeline drugs, with opinion leader comment and region-specific sales forecasts to 2018.

Generic market share is predicted to grow substantially by 2018 and prospective players in the symptomatic relief drug class in particular can expect tough competition. Commercial and clinical differentiation is key for a new drug's success and GlaxoSmithKline's Duodart (tamsulosin + dutasteride) appears well placed to achieve this.

BPH is an indication expansion opportunity for drugs approved for prostate cancer. In addition, there seems to be a general R&D effort to find therapies that will substitute the need of BPH related surgery. One such example is the development of intraprostatic injections that provide local prostate tissue loss while minimizing systemic effects.

Drugs with novel mechanisms of action, such as Nymox's NX-1207 (intraprostatic injection), are commercially attractive, demanding a price premium over current treatments. By offering alternative treatment to patients with severe BPH who would otherwise have undergone surgery, NX-1207 has potential to grow the market, although safety is a concern.

Analyze competitive environment at time of product launch.

Validate internal forecasts and market potential for pipeline products.

Identify licensing opportunities based on company portfolio and market needs.

Publication: 39904
Library Code: DMHC2481
Type: Report
Format: PDF & SlidePack & DataPack
Pages: 194

Table of Contents
Price: $11,400.00 / €7,619.76

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions